GT Biopharma, Inc. - 8-K Filing
GT Biopharma received an additional 180-day compliance period from Nasdaq until November 16, 2026 to meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. (Items: 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, 9.01 Financial Statements and Exhibits)
Tickers: $GTBP